17,676 results match your criteria Lung Cancer and EGFR


Integrative Proteomic Characterization of Human Lung Adenocarcinoma.

Cell 2020 Jul;182(1):245-261.e17

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of the Chinese Academy of Sciences, Beijing, China. Electronic address:

Genomic studies of lung adenocarcinoma (LUAD) have advanced our understanding of the disease's biology and accelerated targeted therapy. However, the proteomic characteristics of LUAD remain poorly understood. We carried out a comprehensive proteomics analysis of 103 cases of LUAD in Chinese patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2020.05.043DOI Listing

Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression.

Cell 2020 Jul;182(1):226-244.e17

Institute of Chemistry, Academia Sinica, Taipei, Taiwan; Department of Chemistry, National Taiwan University, Taipei, Taiwan. Electronic address:

Lung cancer in East Asia is characterized by a high percentage of never-smokers, early onset and predominant EGFR mutations. To illuminate the molecular phenotype of this demographically distinct disease, we performed a deep comprehensive proteogenomic study on a prospectively collected cohort in Taiwan, representing early stage, predominantly female, non-smoking lung adenocarcinoma. Integrated genomic, proteomic, and phosphoproteomic analysis delineated the demographically distinct molecular attributes and hallmarks of tumor progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2020.06.012DOI Listing

Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma.

Cell 2020 Jul;182(1):200-225.e35

Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, 02142, USA. Electronic address:

To explore the biology of lung adenocarcinoma (LUAD) and identify new therapeutic opportunities, we performed comprehensive proteogenomic characterization of 110 tumors and 101 matched normal adjacent tissues (NATs) incorporating genomics, epigenomics, deep-scale proteomics, phosphoproteomics, and acetylproteomics. Multi-omics clustering revealed four subgroups defined by key driver mutations, country, and gender. Proteomic and phosphoproteomic data illuminated biology downstream of copy number aberrations, somatic mutations, and fusions and identified therapeutic vulnerabilities associated with driver events involving KRAS, EGFR, and ALK. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2020.06.013DOI Listing

Progress and current status of molecule-targeted therapy and drug resistance in gastric cancer.

Drugs Today (Barc) 2020 Jul;56(7):469-482

The Third Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

Gastric cancer is one of the most common malignant tumors in the world. In China, its morbidity and mortality are second only to lung cancer. Chemotherapy combined with targeted therapy brings survival benefits to patients with advanced gastric cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1358/dot.2020.56.7.3112071DOI Listing

Topological Transformation-Based Nanobarcoding for Detection and Enumeration of MicroRNAs and Single Nucleotide Polymorphism.

Adv Biosyst 2019 Jul 13;3(7):e1900013. Epub 2019 Jun 13.

School of Chemical Engineering, Sungkyunkwan University, Suwon, Gyeonggi-do, 16419, South Korea.

RNA biomarkers have been recently reported to be associated tightly with the diagnosis and prognosis of many diseases. Particularly, cancers considered to be a serious threat to primates are known to be vastly dominated by genetic networks where RNA plays a key role. RNAs are thus recognized as a major target group that can be used for numerous cancer treatments and it is still required to identify and enumerate them in an effective manner. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/adbi.201900013DOI Listing

Treatment response to intrathecal chemotherapy with pemetrexed via an Ommaya reservoir in EGFR-mutated leptomeningeal metastases from non-small cell lung cancer: a case report.

Ann Palliat Med 2020 Jun 30. Epub 2020 Jun 30.

Department of Geriatric Oncology, Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.

Leptomeningeal metastasis (LM) is one of the most severe complications of non-small cell lung cancer (NSCLC), and it lacks standard treatment guidelines and is always accompanied by poor prognosis. We report a patient who was definitively diagnosed as LM from NSCLC with a targeted mutation of epidermal growth factor receptor (EGFR) via magnetic resonance imaging (MRI) and positive cerebrospinal fluid (CSF) cytology. Tyrosine kinase inhibitors (TKIs) were implemented but ineffective. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/apm-19-521DOI Listing

Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report.

Ann Palliat Med 2020 Jun 29. Epub 2020 Jun 29.

Department of Thoracic Oncology, Cancer Center, West China Hospital, Medical School, Sichuan University, Chengdu, China.

Epidermal growth factor receptor (EGFR) L861Q mutation is a non-classical mutation, with a low incidence, poor response, and uncertain resistance mechanisms when treated by an EGFR tyrosine kinase inhibitor (EGFR-TKI). The liver is one of the most common distant organs to metastasize in nonsmall cell lung cancer (NSCLC), and achieving complete remission treatment for the liver is difficult. In this report, a patient was diagnosed with advanced lung adenocarcinoma harboring the EGFR L861Q mutation and responded well to afatinib for 16 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/apm-19-482DOI Listing

Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors.

Cancer Immunol Immunother 2020 Jul 10. Epub 2020 Jul 10.

Department of Allergy and Respiratory Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama, 700-8558, Japan.

Objectives: Immune checkpoint inhibitors (ICIs) are less effective in non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. However, a small percentage of patients with EGFR-mutant NSCLC do respond, and the characteristics of these patients are not known. Here, we identify the characteristics of patients who may respond to ICI therapy for EGFR-mutant NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-020-02662-0DOI Listing

Thrombin is a therapeutic target for non-small-cell lung cancer to inhibit vasculogenic mimicry formation.

Signal Transduct Target Ther 2020 Jul 10;5(1):117. Epub 2020 Jul 10.

Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, Shanghai, China.

Tumor cells transform into endothelial cells by epithelial-to-mesenchymal transition, which is characterized by vasculogenic mimicry (VM). VM not only accelerates tumor progression but also increases drug-induced resistance. However, very little is currently known about the molecular determinants that enable VM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41392-020-0167-1DOI Listing

Establishment and validation of a novel droplet digital PCR assay for ultrasensitive detection and dynamic monitoring of EGFR mutations in peripheral blood samples of non-small-cell lung cancer patients.

Clin Chim Acta 2020 Jul 6. Epub 2020 Jul 6.

The Fifth Medical Center, General Hospital of PLA, Beijing, 100071, China. Electronic address:

Background: Droplet digital PCR (ddPCR)-based blood detection of EGFR mutations plays significant roles in the individualized therapy of non-small-cell lung cancer (NSCLC) patients. However, a standard assay that is approved by health authorities is still lacking. Additionally, the proper application of this method in clinical settings also needs further investigation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cca.2020.07.003DOI Listing

A Patient With Newly Diagnosed, Advanced EGFR-Mutated Non-Small Cell Lung Cancer.

Oncology (Williston Park) 2020 Jan;34(1):21-27

Thoracic Oncology Unit, Instituto Nacional de Cancerología, México City, México.

A 40-year-old woman presented with a productive cough and shortness of breath that limited her regular activities. Her past medical history was relevant for hypertension since 2016; it is well controlled and treated with enalapril 5 mg twice daily. She also revealed a past wood smoke exposure of 2 hours per day for 10 years during her childhood. Read More

View Article

Download full-text PDF

Source
January 2020

The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases.

Neurooncol Adv 2020 Jan-Dec;2(1):vdaa064. Epub 2020 May 28.

Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.

Background: Molecular and genetic alterations of non-small-cell lung cancer (NSCLC) now play a vital role in patient care of this neoplasm. The authors focused on the impact of epidermal growth factor receptor mutation (EGFR-mt) status on the survival of patients after brain metastases (BMs) from NSCLC. The purpose of the study was to understand the most desirable management of BMs from NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/noajnl/vdaa064DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284117PMC

Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer.

J Thorac Dis 2020 May;12(5):2896-2909

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.

As the incidence of cancer increases worldwide there is an unmet need to understand cancer evolution to improve patient outcomes. Our growing knowledge of cancer cells' clonal expansion, heterogeneity, adaptation, and relationships within the tumor immune compartment and with the tumor microenvironment has made clear that cancer is a disease that benefits from heterogeneity and evolution. This review outlines recent knowledge of non-small cell lung cancer (NSCLC) pathogenesis and tumor progression from an evolutionary standpoint, focused on the role of oncogenic driver mutations as epidermal growth factor receptor (). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2019.08.31DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330358PMC

Impact of concurrent genomic alterations in epidermal growth factor receptor ()-mutated lung cancer.

J Thorac Dis 2020 May;12(5):2883-2895

Department of Medicine, University of California, San Francisco, California, USA.

Comprehensive characterization of the genomic landscape of epidermal growth factor receptor ()-mutated lung cancers have identified patterns of secondary mutations beyond the primary oncogenic mutation. These include concurrent pathogenic alterations affecting p53 (60-65%), RTKs (5-10%), PIK3CA/KRAS (3-23%), Wnt (5-10%), and cell cycle (7-25%) pathways as well as transcription factors such as MYC and NKX2-1 (10-15%). The majority of these co-occurring alterations were detected or enriched in samples collected from patients at resistance to tyrosine kinase inhibitor (TKI) treatment, indicating a potential functional role in driving resistance to therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2020.03.78DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330397PMC

Applications of cell-free circulating tumor DNA detection in EGFR mutant lung cancer.

J Thorac Dis 2020 May;12(5):2877-2882

University of California San Diego, La Jolla, CA, USA.

Analyses of cell-free tumor DNA (ctDNA) have provided a non-invasive strategy for cancer diagnosis, the identification of molecular aberrations for treatment identification, and evaluation of tumor response. Sensitive and specific ctDNA sequencing strategies have allowed for implementation into clinical practice for the initial genotyping of patients and resistance monitoring. The specific need for EGFR mutation detection for the management of lung cancer patients has been an early imperative and has set the stage for non-invasive molecular profiling across other oncogenic drivers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2020.01.66DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330324PMC

Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors.

J Thorac Dis 2020 May;12(5):2859-2876

Department of Internal Medicine, Division of Hematology and Oncology, UC Davis School of Medicine and UC Davis Comprehensive Cancer Center, Sacramento, CA, USA.

Next-generation sequencing (NGS) of tumor samples and circulating tumor DNA has revolutionized diagnostic and therapeutic strategies in lung cancer. The identification of the epidermal growth factor receptor (EGFR) oncogenic driver has translated into successful therapy of advanced lung cancer using EGFR tyrosine kinase inhibitors (TKI). Unfortunately, responses are limited by acquired mechanisms of resistance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2019.08.32DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330402PMC

Mechanisms of resistance to osimertinib.

J Thorac Dis 2020 May;12(5):2851-2858

Medical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, Messina, Italy.

The introduction of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has significantly improved the prognosis of advanced non-small cell lung cancer (NSCLC) patients with mutations. The most common mechanism of acquired resistance to first- and second-generation EGFR TKIs is represented by the secondary mutation. Osimertinib, a third-generation TKI designed to target both EGFR sensitizing mutations and T790M, was first approved for the treatment of EGFR T790M mutation-positive NSCLC patients in progression after EGFR TKI therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2019.08.30DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330330PMC

Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q.

J Thorac Dis 2020 May;12(5):2771-2780

Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.

Epidermal growth factor receptor (EGFR) L718Q is a rare resistant mutation which independently leads to third-generation tyrosine kinase inhibitor (TKI) resistance. Although a few studies have examined its resistance mechanisms, no effective treatment strategy has yet been proposed for patients with this mutation. Here, we report an effective treatment strategy for the rare EGFR L718Q mutation for the first time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2020.03.29DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330377PMC

Non-significant efficacy of icotinib plus pleurodesis in epidermal growth factor receptor positive mutant lung cancer patients after malignant pleural effusion drainage compared to icotinib alone.

J Thorac Dis 2020 May;12(5):2499-2506

Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China.

Background: To investigate the efficacy and safety of icotinib plus pleurodesis or icotinib alone in epidermal growth factor receptor (EGFR) positive mutant lung cancer patients after malignant pleural effusion (MPE) drainage.

Methods: In this retrospective study from initially reviewed case reports of 230 lung adenocarcinoma patients with MPE who were EGFR mutation positive and treated in our hospital between Jan 2014 and Dec 2016 consecutively, 51 patients who met the inclusion criteria were divided into treated with oral icotinib plus pleurodesis and without pleurodesis after pleural effusion drainage groups. Case records including patient gender, age, smoking status and local treatments, as well as adverse events were collected and retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2020.03.49DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330332PMC

Combination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase II trial.

J Thorac Dis 2020 May;12(5):2450-2458

Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing 210009, China.

Background: This trial aimed to investigate the treatment response, survival profiles and treatment-related adverse events (AEs) of apatinib plus docetaxel in advanced non-squamous non-small cell lung cancer (NSCLC) patients with wild-type epidermal growth factor receptor (EGFR).

Methods: Thirty advanced non-squamous NSCLC patients with wild-type EGFR were recruited in this multi-center, phase II trial. All patients received apatinib (orally 500 mg, once daily until disease progression, intolerable toxicity, or death) plus docetaxel (intravenously 60 mg/m at day 1 every 3 weeks for 4-6 cycles). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2020.03.54DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330342PMC

Sub-solid lung adenocarcinoma in Asian versus Caucasian patients: different biology but similar outcomes.

J Thorac Dis 2020 May;12(5):2161-2171

Division of Thoracic Surgery, Department of Cardiothoracic Surgery, Stanford University, Stanford, CA, USA.

Background: Asian and Caucasian patients with lung cancer have been compared in several database studies, with conflicting findings regarding survival. However, these studies did not include proportion of ground-glass opacity or mutational status in their analyses. Asian patients commonly develop sub-solid lung adenocarcinomas that harbor EGFR mutations, which have a better prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2020.04.37DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330405PMC

Clinical significance of anemia as a prognostic factor in non-small cell lung cancer carcinoma with activating epidermal growth factor receptor mutations.

J Thorac Dis 2020 May;12(5):1895-1902

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Background: Anemia is a frequent finding in cancer patients. Pre-treatment anemia is known to be associated with poor survival after surgery or stereotactic body radiation therapy of non-small cell lung cancer (NSCLC). However, little study was conducted in NSCLC with activating epidermal growth factor receptor (EGFR) mutations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd-19-3932DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330305PMC

Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.

Sci Rep 2020 Jul 8;10(1):11236. Epub 2020 Jul 8.

Department of Respiratory Medicine, The Second Hospital of Jilin University, 218 Ziqiang Street, Nanguan District, Changchun, 130041, Jilin, People's Republic of China.

Epidermal growth factor receptor- tyrosine kinase inhibitors (EGFR-TKIs) have shown promise against non-small cell lung cancers (NSCLCs) in clinics but the utility is often short-lived because of T790M mutations in EGFR that help evade TKIs' action. Osimertinib is the third and latest generation TKI that targets EGFRs with T790M mutations. However, there are already reports on acquired resistance against Osimertinib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-67908-4DOI Listing

Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator).

Clin Lung Cancer 2020 May 23. Epub 2020 May 23.

Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.

Background: Osimertinib is a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that potently and selectively inhibits EGFR activating and EGFR T790M resistance mutations. Osimertinib was found to be more effective than first-generation EGFR-TKIs in patients with previously untreated advanced non-small-cell lung cancer (NSCLC) harboring EGFR-positive mutations in a prior phase III trial. Osimertinib is, therefore, one of the most important standard therapies for EGFR mutation-positive patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2020.05.023DOI Listing

Influence of Biopsy Technique on Molecular Genetic Tumor Characterization in Non-Small Cell Lung Cancer-The Prospective, Randomized, Single-Blinded, Multicenter PROFILER Study Protocol.

Diagnostics (Basel) 2020 Jul 6;10(7). Epub 2020 Jul 6.

Department of Medical Oncology and Pneumology, Eberhard Karls University, 72076 Tübingen, Germany.

The detection of molecular alterations is crucial for the individualized treatment of advanced non-small cell lung cancer (NSCLC). Missing targetable alterations may have a major impact on patient's progression free and overall survival. Although laboratory testing for molecular alterations has continued to improve; little is known about how biopsy technique affects the detection rate of different mutations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/diagnostics10070459DOI Listing

Propensity score analysis of overall survival between first- and second-generation EGFR-TKIs using the Real-World Data.

Cancer Sci 2020 Jul 8. Epub 2020 Jul 8.

Department of Thoracic Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku Nagoya, Nagoya, Aichi, 464-8681, Japan.

We constructed a data set of EGFR-mutant NSCLC patients, and compared the overall survival of first-generation (1G), and second-generation (2G) EGFR-TKIs in clinical practice using propensity score. We reviewed the clinical data of consecutive EGFR-mutated NSCLC patients who received EGFR-TKI therapy between Jan 2008 and Aug 2017 at 11 institutions in Japan. The primary endpoint was OS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.14560DOI Listing

Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer.

Cancer Chemother Pharmacol 2020 Jul 8. Epub 2020 Jul 8.

Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osakasayama City, Osaka, 5898511, Japan.

Purpose: This phase I study was conducted to evaluate the safety and pharmacokinetics of YM155, a potent, selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer (NSCLC).

Methods: The pimary objectives were to evaluate the safety and tolerability of YM155 at escalating doses (3.6, 4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-020-04112-1DOI Listing

Affibody-Modified Gd@C-Dots with Efficient Renal Clearance for Enhanced MRI of EGFR Expression in Non-Small-Cell Lung Cancer.

Int J Nanomedicine 2020 30;15:4691-4703. Epub 2020 Jun 30.

NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Molecular Imaging Research Center (MIRC), Harbin Medical University, Harbin, Heilongjiang, 150028, People's Republic of China.

Purpose: Gd-encapsulated carbonaceous dots (Gd@C-dots) have excellent stability and magnetic properties without free Gd leakage, therefore they can be considered as a safe alternative T1 contrast agent to commonly used Gd complexes. To improve their potential for cancer diagnosis and treatment, affibody-modified Gd@C-dots targeting non-small-cell lung cancer (NSCLC) EGFR-positive tumors with enhanced renal clearance were developed and synthesized.

Materials And Methods: Gd@C-dots were developed and modified with Ac-Cys-Z through EDC/NHS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/IJN.S244172DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335283PMC

Nationwide Real-world Cohort Study of First-line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer.

Clin Lung Cancer 2020 May 22. Epub 2020 May 22.

Department of Respiratory Medicine, Medical Center Leeuwarden, Leeuwarden, The Netherlands.

Background: Only a few randomized trials directly compared the relative efficacy of tyrosine kinase inhibitors (TKIs) in patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), and most trials comprised selected series from Asian populations. Therefore, the aim of this study was to assess the overall survival (OS) of advanced EGFR-mutated NSCLC in a large white population and to evaluate variation between different TKIs and identify predictors of survival.

Patients And Methods: Information about clinical characteristics, treatment, and survival for 873 patients with stage IV EGFR + NSCLC, diagnosed from 2015 through 2017, was derived from the Netherlands Cancer Registry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2020.05.019DOI Listing

miR-365a-5p suppresses gefitinib resistance in non-small-cell lung cancer through targeting PELI3.

Pharmacogenomics 2020 Jul 8. Epub 2020 Jul 8.

Department of Thoracic Surgery, The Second Hospital of Hebei Medical University, No. 215 Heping West Road, Shijiazhuang, Hebei, 050000, China.

Demonstrate the function of dysregulated miR-365a-5p-PELI3 signaling axis in the generation of gefitinib resistance during treatment for non-small-cell lung cancer (NSCLC). All the NSCLC patients who participated in this research were recruited from the Second Hospital of Hebei Medical University (Shijiazhuang, China). PC9 cells and PC9GR cells were cultured for experiments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2020-0006DOI Listing

Improving Plasmonic Photothermal Therapy of Lung Cancer Cells with Anti-EGFR Targeted Gold Nanorods.

Nanomaterials (Basel) 2020 Jul 3;10(7). Epub 2020 Jul 3.

School of Electronic and Electrical Engineering, University of Leeds, Leeds LS2 9JT, UK.

Lung cancer is a particularly difficult form of cancer to diagnose and treat, due largely to the inaccessibility of tumours and the limited available treatment options. The development of plasmonic gold nanoparticles has led to their potential use in a large range of disciplines, and they have shown promise for applications in this area. The ability to functionalise these nanoparticles to target to specific cancer types, when combined with minimally invasive therapies such as photothermal therapy, could improve long-term outcomes for lung cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/nano10071307DOI Listing

Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019.

J Natl Compr Canc Netw 2020 Jul;18(7):866-872

1Department of Clinical Pharmacy, UCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), San Francisco.

Background: Clinical adoption of the sequencing of circulating tumor DNA (ctDNA) for cancer has rapidly increased in recent years. This sequencing is used to select targeted therapy and monitor nonresponding or progressive tumors to identify mechanisms of therapeutic resistance. Our study objective was to review available coverage policies for cancer ctDNA-based testing panels to examine trends from 2015 to 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2020.7542DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347155PMC

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.

Ann Oncol 2020 Jul 4. Epub 2020 Jul 4.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address:

Background: Up to 40% of patients with non-small cell lung cancer (NSCLC) and EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs) present with disease progression in the central nerve system (CNS), either as brain metastases (BM) or leptomeningeal metastases (LM). Osimertinib (80mg), a third generation, irreversible, oral EGFR TKI, has shown efficacy in active CNS metastases. However, efficacy of 160mg osimertinib in BM or LM is unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.06.017DOI Listing

First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation.

J Cancer Res Clin Oncol 2020 Jul 7. Epub 2020 Jul 7.

Service de Pneumologie, Centre Hospitalier Intercommunal de Créteil, Créteil, France.

Purpose: Erlotinib is indicated as first-line treatment for patients with non-small-cell lung cancer (NSCLC) harboring an epidermal growth-factor-receptor (EGFR) mutation. Addition of a vascular endothelial growth factor (VEGF) inhibitor (anti-VEGF) in combination with the tyrosine-kinase inhibitor erlotinib in this setting is controversial.

Methods: We conducted a meta-analysis of randomized trials comparing anti-VEGF plus erlotinib vs erlotinib alone as first-line therapy for advanced NSCLC harboring an EGFR mutation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-020-03311-wDOI Listing

Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.

Clin Ther 2020 Jul 3. Epub 2020 Jul 3.

Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Switzerland; School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland. Electronic address:

Purpose: Erlotinib is an oral first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for non-small cell lung cancers (NSCLC) with EGFR-activating mutations. Older patients experience more toxicities compared with younger patients at the standard recommended dose of 150 mg once daily. The aims of this study were to describe the pharmacokinetic profile of erlotinib in unselected patients with NSCLC, to quantify and explain its variability, to challenge the standard recommended dose in older patients, and to propose clinical recommendations for the therapeutic management of patients taking erlotinib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinthera.2020.05.008DOI Listing

The ATF6-EGF Pathway Mediates the Awakening of Slow-Cycling Chemoresistant Cells and Tumor Recurrence by Stimulating Tumor Angiogenesis.

Cancers (Basel) 2020 Jul 2;12(7). Epub 2020 Jul 2.

Creative Research Initiative Center for concurrent control of emphysema and lung cancer, College of Pharmacy, Seoul National University, Seoul 08826, Korea.

Slow-cycling cancer cells (SCCs) with a quiescence-like phenotype are believed to perpetrate cancer relapse and progression. However, the mechanisms that mediate SCC-derived tumor recurrence are poorly understood. Here, we investigated the mechanisms underlying cancer recurrence after chemotherapy, focusing on the interplay between SCCs and the tumor microenvironment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12071772DOI Listing

Undetectable circulating tumor DNA levels correlate with low risk of recurrence/metastasis in postoperative pathologic stage I lung adenocarcinoma patients.

Lung Cancer 2020 Jun 20;146:327-334. Epub 2020 Jun 20.

Department of Thoracic Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China. Electronic address:

Objectives: The application of circulating tumor DNA (ctDNA) monitoring after resection in pathologic(p) stage I lung adenocarcinoma (LUAD) patients remains controversial and it is of great clinical interest to decipher the difference of genetic features between ground-glass opacity (GGO) and solid nodules (non-GGO) subgroups. We aim to assess the utility of ctDNA in tracking early recurrence or metastasis following surgery and reveal the genetic differences between GGO and non-GGO.

Materials And Methods: Tumor tissues and matched postoperative plasma samples were collected from a total of 82 (p)stage I LUAD patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2020.06.009DOI Listing

Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC.

Clin Lung Cancer 2020 May 16. Epub 2020 May 16.

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2020.05.009DOI Listing

Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis.

Clin Lung Cancer 2020 May 22. Epub 2020 May 22.

Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Division of Pulmonary Inflammation, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Introduction: Thyroid transcription factor 1 (TTF-1) is a prognostic biomarker in lung adenocarcinoma; however, TTF-1-positive patients also display more favorable factors like actionable target mutations. In contrast, TTF-1-negative cancer is a poorly described entity. We performed a retrospective study to characterize a TTF-1-negative phenotype and to evaluate outcome depending on the chemotherapy regimen applied in the EGFR/ALK-negative population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2020.05.014DOI Listing

EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the Literature.

Clin Lung Cancer 2020 May 23. Epub 2020 May 23.

Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2020.05.016DOI Listing
May 2020
3.104 Impact Factor

The feasibility and usability of DNA-dot bioconjugation to antibody for targeted in vitro cancer cell fluorescence imaging.

J Photochem Photobiol B 2020 Jun 26;209:111944. Epub 2020 Jun 26.

Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address:

DNA-protein bioconjugation is an appealing target-tracking strategy. The new capability of DNA molecule as a biological nanomaterial endows unique fluorescence and physicochemical properties to be applied in bioimaging. Progression in targeted imaging is contingent on the conjugation of diagnostic nanoparticles to biomolecular signatures, particularly antibody-based ligands. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jphotobiol.2020.111944DOI Listing

Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer.

Lung Cancer 2020 Jun 26;146:310-317. Epub 2020 Jun 26.

Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, 3010, Australia.

Background: KRAS mutations are found in 20-30 % of non-small cell lung cancers (NSCLC) and were traditionally considered undruggable. KRAS mutation confers sensitivity to KRAS covalent inhibitors, however its prognostic impact remains unclear. This study assesses the frequency, clinical features, prevalence of brain metastases and outcomes in KRAS NSCLC in a real-world setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2020.06.030DOI Listing

Disease-related cellular protein networks differentially affected under different EGFR mutations in lung adenocarcinoma.

Sci Rep 2020 Jul 2;10(1):10881. Epub 2020 Jul 2.

Department of Chest Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, 216-8511, Japan.

It is unclear how epidermal growth factor receptor EGFR major driver mutations (L858R or Ex19del) affect downstream molecular networks and pathways. This study aimed to provide information on the influences of these mutations. The study assessed 36 protein expression profiles of lung adenocarcinoma (Ex19del, nine; L858R, nine; no Ex19del/L858R, 18). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-67894-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331587PMC

Focal Leptomeningeal Disease with Perivascular Invasion in -Mutant Non-Small-Cell Lung Cancer.

AJNR Am J Neuroradiol 2020 Jul 2. Epub 2020 Jul 2.

From the Department of Radiation Oncology (A.D., F.Y.M., D.B.S.)

We report a previously undescribed pattern of brain metastases in patients with e-mutated non-small-cell lung cancer treated with tyrosine kinase inhibitors and radiation therapy. These highly distinct lesions appear to spread focally within the leptomeninges, with invasion along the perivascular spaces (FLIP). The survival of patients with FLIP was significantly better compared with patients with classic leptomeningeal disease (median survival, 21 versus 3 months; = . Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3174/ajnr.A6640DOI Listing

In vitro antitumor effect of cucurbitacin E on human lung cancer cell line and its molecular mechanism.

Chin J Nat Med 2020 Jul;18(7):483-490

Institute of Agricultural Biotechnology, Jilin Academy of Agricultural Sciences, Changchun 130033, China. Electronic address:

Cucurbitacin E (CuE) is previously reported to exhibit antitumor effect by several means. In this study, CuE acted as a tyrosine kinase inhibitor interfering with the epidermal growth factor receptor/mitogen-activated protein kinase (EGFR/MAPK) signaling pathway and subsequently induced apoptosis and cell cycle arrest in non-small-cell lung cancer (NSCLC) cell line A549. The apoptosis regulators, cleaved Caspases-3 and Caspases-9, were observed to be increased with the treatment of CuE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1875-5364(20)30058-3DOI Listing

Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.

Expert Opin Emerg Drugs 2020 Jul 2. Epub 2020 Jul 2.

Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine , Osaka-Sayama, Japan.

Introduction: aberrations, including exon 14 skipping mutation and amplification, are present in ~5% of non-small cell lung cancer (NSCLC) cases, and these levels are comparable to the frequency of fusion. amplification also occurs as an acquired resistance mechanism in -mutated NSCLC after EGFR tyrosine kinase inhibitors (TKI) treatment failure. Therefore, the development of therapies for activated MET is urgently needed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2020.1791821DOI Listing

Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis.

Curr Med Res Opin 2020 Jul 2. Epub 2020 Jul 2.

Rush University Medical Center, Chicago, Illinois, United States of America.

Timely assessment of patient-specific prognosis is critical to oncology care involving a shared decision-making approach, but clinical prognostic factors traditionally used in NSCLC have limitations. We examine a proteomic test to address these limitations. This study examines the prognostic performance of the VeriStrat blood-based proteomic test that measures the inflammatory disease state of patients with advanced NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/03007995.2020.1790346DOI Listing

Clinical impacts of EGFR mutation status: analysis of 5,780 surgically resected lung cancer cases.

Ann Thorac Surg 2020 Jun 29. Epub 2020 Jun 29.

Department of General Thoracic Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8677, Japan.

Background: To elucidate the clinical, pathologic, and prognostic impacts of EGFR mutation and mutation subtypes in early-stage lung cancer, we conducted a retrospective analysis of the Japanese Joint Committee of Lung Cancer Registry database (a nationwide database for surgically-resected lung cancer patients; n = 18,973).

Methods: Of 13,951 patients classified as non-squamous non-small cell lung cancer in the database, 5,780 patients (41.0%) had been tested for EGFR mutation and were included in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2020.05.041DOI Listing

Molecular matching and treatment strategies for advanced stage lung cancer at Dartmouth-Hitchcock Medical Center: A three-year review of a Molecular Tumor Board.

Pract Lab Med 2020 Aug 12;21:e00174. Epub 2020 Jun 12.

Department of Pathology and Laboratory Medicine, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.

Matching of actionable tumor mutations with targeted therapy increases response rates and prolongs survival in lung cancer patients. Drug development and trials targeting genetic alterations are expanding rapidly. We describe the role of a Molecular Tumor Board (MTB) in the design of molecularly informed treatment strategies in our lung cancer patient population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.plabm.2020.e00174DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322356PMC